PHARMACEUTICAL HOLDRS TRUST - FORM 8-K - EX-99.1 - EXHIBIT 99.1 - November 10, 2009

Attached files

file filename
8-K - FORM 8-K - PHARMACEUTICAL HOLDRS TRUSTss77208_8k.htm
 
PROSPECTUS SUPPLEMENT
EXHIBIT 99.1
(To Prospectus dated March 11, 2009)
REGISTRATION NO.  333-92161

 

 
1,000,000,000 Depositary Receipts
Pharmaceutical HOLDRS (SM) Trust
 
This prospectus supplement supplements information contained in the prospectus dated March 11, 2009 relating to the sale of up to 1,000,000,000 depositary receipts by the Pharmaceutical HOLDRS Trust.
 
The share amounts specified in the table in the “Highlights of Pharmaceutical HOLDRS” section of the base prospectus shall be replaced with the following:
 
Name of Company1
 
Ticker
  
Share
Amounts
  
Primary
Trading
Market
Abbott Laboratories
  
ABT
  
14.0000
    
NYSE
Allergan, Inc.
  
AGN
  
2.0000
    
NYSE
Biovail Corporation
  
BVF
  
4.0000
    
NYSE
Bristol-Myers Squibb Company
  
BMY
  
18.0000
    
NYSE
Eli Lilly & Company
  
LLY
  
10.0000
    
NYSE
Forest Laboratories, Inc.
  
FRX
  
4.0000
    
NYSE
Hospira, Inc.
  
HSP
  
1.4000
    
NYSE
Johnson & Johnson
  
JNJ
  
26.0000
    
NYSE
King Pharmaceuticals, Inc.
  
KG
  
4.2500
    
NYSE
Medco Health Solutions, Inc.
  
MHS
  
5.3064
    
NYSE
Merck & Co., Inc.
  
MRK
  
30.0738
    
NYSE
Mylan Laboratories, Inc.
  
MYL
  
2.2500
    
NASDAQ
Pfizer Inc.
  
PFE
  
69.8200
    
NYSE
Valeant Pharmaceuticals
  
VRX
  
1.0000
    
NYSE
Watson Pharmaceuticals, Inc.
  
WPI
  
1.0000
    
NYSE
Zimmer Holdings Inc.
  
ZMH
  
1.8000
    
NYSE

The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.

The date of this prospectus supplement is November 10, 2009.

 
1 On November 5, 2009, the merger of Schering-Plough Corporation and Merck & Co., Inc. became effective.  As a result, Schering-Plough Corporation will no longer be an underlying constituent of the Pharmaceutical HOLDRS Trust.  In connection with the merger, Schering-Plough Corporation shareholders will receive 0.5767 shares of Merck & Co., Inc. and $10.50 in cash for each share of Schering-Plough Corporation.  The Bank of New York Mellon will receive 8.0738 shares of Merck & Co., Inc. and $147.00 per 100 share round lot of Pharmaceutical HOLDRS.  As a result, once the allocation has been completed by The Depository Trust Company, creations of Pharmaceutical HOLDRS will require a deposit of 30.0738 shares of Merck & Co., Inc. per 100 share round lot of Pharmaceutical HOLDRS.
 
 
 

Also read